Phosphoryl transfer is not rate-limiting for the ROCK I-catalyzed kinase reaction.
Rho-associated coiled-coil kinase, ROCK, is implicated in Rho-mediated cell adhesion and smooth muscle contraction. Animal models suggest that the inhibition of ROCK can ameliorate conditions, such as vasospasm, hypertension, and inflammation. As part of our effort to design novel inhibitors of ROCK, we investigated the kinetic mechanism of ROCK I. Steady-state bisubstrate kinetics, inhibition kinetics, isotope partition analysis, viscosity effects, and presteady-state kinetics were used to explore the kinetic mechanism. Plots of reciprocals of initial rates obtained in the presence of nonhydrolyzable ATP analogues and the small molecule inhibitor of ROCK, Y-27632, against the reciprocals of the peptide concentrations yielded parallel lines (uncompetitive pattern). This pattern is indicative of an ordered binding mechanism, with the peptide adding first. The staurosporine analogue K252a, however, gave a noncompetitive pattern. When a pulse of (33)P-gamma-ATP mixed with ROCK was chased with excess unlabeled ATP and peptide, 0.66 enzyme equivalent of (33)P-phosphate was incorporated into the product in the first turnover. The presence of ATPase activity coupled with the isotope partition data is a clear evidence for the existence of a viable [E-ATP] complex in the kinase reaction and implicates a random binding mechanism. The k(cat)/K(m) parameters were fully sensitive to viscosity (viscosity effects of 1.4 +/- 0.2 and 0.9 +/- 0.3 for ATP and peptide 5, respectively), and therefore, the barriers to dissociation of either substrate are higher than the barrier for the phosphoryl transfer step. As a consequence, not all the binding steps are at fast equilibrium. The observation of a burst in presteady-state kinetics (k(b) = 10.2 +/- 2.1 s(-)(1)) and the viscosity effect on k(cat) of 1.3 +/- 0.2 characterize the phosphoryl transfer step to be fast and the release of product and/or the enzyme isomerization step accompanying it as rate-limiting at V(max) conditions. From the multiple kinetic studies, most of the rate constants for the individual steps were either evaluated or estimated.
Futer
Olga
O
Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139-4242, USA.
Saadat
Ahmad R
AR
Doran
John D
JD
Raybuck
Scott A
SA
Pazhanisamy
S
S
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000577:Amides / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D006801:Humans; D026121:Indole Alkaloids; D047908:Intracellular Signaling Peptides and Proteins; D007700:Kinetics; D010766:Phosphorylation; D011487:Protein Conformation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D012997:Solvents; D013379:Substrate Specificity; D014783:Viscosity; D054460:rho-Associated Kinases
D000577:Amides; D002227:Carbazoles; D026121:Indole Alkaloids; D047908:Intracellular Signaling Peptides and Proteins; D011725:Pyridines; D012997:Solvents; C108830:Y 27632; C049985:staurosporine aglycone; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; D000251:Adenosine Triphosphatases